{"id":"NCT02553772","sponsor":"Allergan","briefTitle":"A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.","officialTitle":"A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-01-06","primaryCompletion":"2016-09-09","completion":"2016-09-09","firstPosted":"2015-09-18","resultsPosted":"2017-11-17","lastUpdate":"2017-11-17"},"enrollment":242,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Syndromes"],"interventions":[{"type":"DRUG","name":"Carboxymethylcellulose Based Eye Drop","otherNames":[]},{"type":"DRUG","name":"Carboxymethylcellulose Sodium 0.5%","otherNames":["REFRESH OPTIVE® ADVANCED"]}],"arms":[{"label":"OM3 Tear","type":"EXPERIMENTAL"},{"label":"REFRESH OPTIVE® ADVANCED","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate the safety and efficacy of a new eye drop formulation in patients with dry eye disease.","primaryOutcome":{"measure":"Change From Baseline in the Ocular Surface Disease Index© (OSDI©) Score","timeFrame":"Baseline, Day 90","effectByArm":[{"arm":"OM3 Tear","deltaMin":41.12,"sd":12.68},{"arm":"REFRESH OPTIVE® ADVANCED","deltaMin":39.63,"sd":11.33}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":13,"countries":["United States","Australia"]},"refs":{"pmids":[],"seeAlso":["http://www.allerganclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":120},"commonTop":[]}}